A
Annette Schmitt-Graeff
Researcher at University of Freiburg
Publications - 156
Citations - 9123
Annette Schmitt-Graeff is an academic researcher from University of Freiburg. The author has contributed to research in topics: Bone marrow & Transplantation. The author has an hindex of 43, co-authored 150 publications receiving 7283 citations. Previous affiliations of Annette Schmitt-Graeff include University Medical Center Freiburg.
Papers
More filters
Journal ArticleDOI
IgG4-related disease.
Journal ArticleDOI
Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.
Desirée Schubert,Desirée Schubert,Claudia Bode,Rupert Kenefeck,Tie Zheng Hou,James B. Wing,Alan Kennedy,Alla Bulashevska,Britt-Sabina Petersen,Alejandro A. Schäffer,Björn Grüning,Susanne Unger,Natalie Frede,Ulrich Baumann,Torsten Witte,Reinhold E. Schmidt,G Dueckers,Tim Niehues,Suranjith L. Seneviratne,Maria Kanariou,Carsten Speckmann,Stephan Ehl,Anne Rensing-Ehl,Klaus Warnatz,Mirzokhid Rakhmanov,Robert Thimme,Peter Hasselblatt,Florian Emmerich,Toni Cathomen,Rolf Backofen,Paul Fisch,Maximilian Seidl,Annette M. May,Annette Schmitt-Graeff,Shinji Ikemizu,Ulrich Salzer,Andre Franke,Shimon Sakaguchi,Lucy S. K. Walker,David M. Sansom,Bodo Grimbacher +40 more
TL;DR: Taking together, mutations in CTLA4 resulting inCTLA-4 haploinsufficiency or impaired ligand binding result in disrupted T and B cell homeostasis and a complex immune dysregulation syndrome.
Journal ArticleDOI
Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans
Ulrich Salzer,Helen Chapel,A. D. B. Webster,Qiang Pan-Hammarström,Annette Schmitt-Graeff,Michael Schlesier,Hans-Hartmut Peter,Jürgen K. Rockstroh,Pascal Schneider,Alejandro A. Schäffer,Lennart Hammarström,Bodo Grimbacher +11 more
TL;DR: Heterozygosity with respect to mutations causing the amino acid substitutions S144X and C104R abrogated APRIL binding and resulted in loss of TACI function, as evidenced by impaired proliferative response to IgM-APRIL costimulation and defective class switch recombination induced by IL-10 and APRIL or BAFF.
Journal ArticleDOI
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation.
Christine Dierks,Christine Dierks,Ronak Beigi,Gui-Rong Guo,Katja Zirlik,Mario R. Stegert,Paul W. Manley,Christopher Trussell,Annette Schmitt-Graeff,Klemens Landwerlin,Hendrik Veelken,Markus Warmuth,Markus Warmuth +12 more
TL;DR: It is shown that Hedgehog signaling is activated in LSCs through upregulation of Smo, and this indicates that Smo inhibition might be an effective treatment strategy to reduce the LSC pool in CML.
Journal ArticleDOI
International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data.
Daniel A. Arber,Attilio Orazi,Robert P. Hasserjian,Michael Horowitz,Katherine R. Calvo,Hans Michael Kvasnicka,Sa A. Wang,Adam Bagg,Tiziano Barbui,Susan Branford,Carlos E. Bueso-Ramos,Jorge E. Cortes,Paola Dal Cin,Courtney D. DiNardo,Hervé Dombret,Eric J. Duncavage,Benjamin L. Ebert,Elihu H. Estey,Fabio Facchetti,Kathryn Foucar,Naseema Gangat,Umberto Gianelli,Lucy A. Godley,Nicola Goekbuget,Jason Gotlib,Eva Hellström-Lindberg,Gabriela S. Hobbs,Roald Hoffmann,Elias Jabbour,Jean-Jacques Kiladjian,Richard A. Larson,Michelle M. Le Beau,Mignon L. Loh,Bob Löwenberg,Elizabeth Macintyre,Luca Malcovati,Charles G. Mullighan,Charlotte M. Niemeyer,Olatoyosi Odenike,Seishi Ogawa,Alberto Orfao,Elli Papaemmanuil,Francesco Passamonti,Kimmo Porkka,C H Pui,Jerald P. Radich,Andreas Reiter,María Rozman,Martina Rudelius,Michael R. Savona,Charles A. Schiffer,Annette Schmitt-Graeff,Akiko Shimamura,Jorge Sierra,Wendy Stock,Richard Stone,Martin S. Tallman,Juergen Thiele,Hwei-Fang Tien,Alexandar Tzankov,Alessandro M. Vannucchi,Paresh Vyas,Andrew H. Wei,Olga Weinberg,Agnieszka Wierzbowska,Mario Cazzola,Hartmut Döhner,Ayalew Tefferi +67 more
TL;DR: The authors, a group with expertise in the clinical, pathologic and genetic aspects of these disorders, developed the International Consensus Classification (ICC), aimed at facilitating diagnosis and prognostication of these neoplasms, improving treatment of affected patients, and allowing the design of innovative clinical trials.